БИБЛИОТЕКА
-
- Фильтр
- Количество записей: 3197
-
- По дате
- По просмотрам
-
Зарубежные материалы
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.
Подробнее
1050
-
Зарубежные материалы
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
The impact of insulin secretagogues (ISs) on long-term major clinical outcomes in type 2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with all available ISs compared with metformin in a nationwide study.
Подробнее
1167
-
Зарубежные материалы
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007–2017
Te International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM). People with diabetes comprise 8.8% of the world’s population, and IDF predicts that the number of cases of diabetes will rise to 642 million by 2040
Подробнее
1042
-
Статьи
Алгоритмы специализированной медицинской помощи больным сахарным диабетом (9-й выпуск)
Данное издание содержит восьмой актуализированный выпуск клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.
Подробнее
1298
-
Зарубежные материалы
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.
Подробнее
939
-
Зарубежные материалы
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium – glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
Подробнее
878
-
Зарубежные материалы
Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial
People with schizophrenia die 10–20 years earlier than the general population, with approximately 75% of deaths resulting from physical illness.1 The twofold increased prevalence of overweight and obesity contributes to this excess mortality.2 Some, but not all, studies suggest that dietary
Подробнее
817
-
Зарубежные материалы
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes.
Подробнее
1055
-
Зарубежные материалы
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
Diabetes mellitus is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without diabetes, patients with type 2 diabetes mellitus have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular disease.
Подробнее
1074
-
Зарубежные материалы
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease.
Подробнее
967
-
Зарубежные материалы
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Подробнее
1041
-
Статьи
Артериальная гипертензия у взрослых
Артериальная гипертензия (АГ) — синдром повышения клинического артериального давления (АД) при гипертонической болезни и симптоматических АГ выше пороговых значений, определенных в результате эпидемиологических и рандомизированных контролируемых исследований, продемонстрировавших связь с повышением сердечнососудистого риска и целесообразность и пользу лечения, направленного на снижение АД ниже ...
Подробнее
1275
-
Зарубежные материалы
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and theEuropeanAssociation for the Study of Diabetes (EASD)
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education ...
Подробнее
946
-
Зарубежные материалы
Obesity and Diabetic Kidney Disease
The prevalence of obesity (body mass index, BMI ≥ 30 kg/m2) has risen to epidemic proportions and continues to be a major health problem worldwide 1–3. The high prevalence of obesity is closely linked to the increased incidence of a number of chronic diseases, including type 2 diabetes, hypertension and cardiovascular disease 2, 4–8.
Подробнее
1287
-
Зарубежные материалы
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (HHS Public Access)
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
Подробнее
1186
- ← Предыдущая
- 1
- ...
- 82
- 83
- 84
- 85 (current)
- 86
- 87
- 88
- ...
- 214
- Следующая →